Search research articles
Contact Us
Filters
Showing results (361-370 of 377) with videos related to
Page
of 38
Sort By:
The Lancet. Oncology
|
June 17, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Marina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
Melissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.
Scientific Reports
|
July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
Laura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
Journal for Immunotherapy of Cancer
|
April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Alessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Journal of Cellular Physiology
|
January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
Eriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Cancers
|
December 17, 2024
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study
Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Cancer Immunology, Immunotherapy : CII
|
June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50
Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 15, 2010
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)
Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, et al.
Page
of 38
Search research articles
Search
Showing results (361-370 of 377) with videos related to
Sort By:
Page
of 38
The Lancet. Oncology
|
June 17, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Marina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
Melissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.
Scientific Reports
|
July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
Laura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
Journal for Immunotherapy of Cancer
|
April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Alessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Journal of Cellular Physiology
|
January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
Eriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Cancers
|
December 17, 2024
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study
Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Cancer Immunology, Immunotherapy : CII
|
June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50
Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 15, 2010
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)
Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, et al.
Page
of 38